Citadel Advisors’s Repare Therapeutics RPTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-16,400
| Closed | -$42.6K | – | 14056 |
|
|
2025
Q4 | $42.6K | Buy |
+16,400
| New | +$33K | ﹤0.01% | 12108 |
|
|
2025
Q3 | – | Sell |
-15,400
| Closed | -$21.4K | – | 13901 |
|
|
2025
Q2 | $21.4K | Buy |
+15,400
| New | +$20.1K | ﹤0.01% | 12089 |
|
|
2024
Q3 | – | Sell |
-1,700
| Closed | -$5.61K | – | 15094 |
|
|
2024
Q2 | $5.61K | Sell |
1,700
-2,200
| -56% | -$7.84K | ﹤0.01% | 13387 |
|
|
2024
Q1 | $18.4K | Sell |
3,900
-11,600
| -75% | -$74.3K | ﹤0.01% | 13065 |
|
|
2023
Q4 | $113K | Sell |
15,500
-800
| -5% | -$4.48K | ﹤0.01% | 10770 |
|
|
2023
Q3 | $197K | Buy |
16,300
+8,700
| +114% | +$89.8K | ﹤0.01% | 9940 |
|
|
2023
Q2 | $80.4K | Hold |
7,600
| – | – | ﹤0.01% | 11246 |
|
|
2023
Q1 | $74.8K | Sell |
7,600
-4,600
| -38% | -$52.8K | ﹤0.01% | 11651 |
|
|
2022
Q4 | $179K | Sell |
12,200
-90,800
| -88% | -$1.36M | ﹤0.01% | 10326 |
|
|
2022
Q3 | $1.25M | Sell |
103,000
-6,200
| -6% | -$79.8K | ﹤0.01% | 6514 |
|
|
2022
Q2 | $1.53M | Sell |
109,200
-2,600
| -2% | -$30.6K | ﹤0.01% | 6096 |
|
|
2022
Q1 | $1.59M | Buy |
111,800
+102,000
| +1,041% | +$1.51M | ﹤0.01% | 6600 |
|
|
2021
Q4 | $207K | Buy |
9,800
+1,400
| +17% | +$33K | ﹤0.01% | 11778 |
|
|
2021
Q3 | $220K | Buy |
8,400
+1,100
| +15% | +$35.5K | ﹤0.01% | 11784 |
|
|
2021
Q2 | $228K | Buy |
+7,300
| New | +$239K | ﹤0.01% | 11879 |
|
Citadel Advisors's RPTX Position: Q1 2026 in Review
Citadel Advisors sold out of Repare Therapeutics (RPTX) in Q1 2026, closing a stake of 238,912 shares — an estimated $621K sold.
Citadel Advisors first reported a position in RPTX in Q2 2020 and held it in 22 quarters. The position peaked at $6.76M in Q2 2021. 0 funds tracked by Wall St. Rank hold RPTX as of Q1 2026.
- Citadel Advisors reported no remaining Repare Therapeutics position as of Q1 2026 after selling out during the quarter.
- Citadel Advisors sold 238,912 Repare Therapeutics shares in Q1 2026, an estimated $621K.
- Citadel Advisors first reported a position in Repare Therapeutics in Q2 2020 and held it in 22 quarters.
- Citadel Advisors's Repare Therapeutics position peaked at $6.76M in Q2 2021.
- 0 funds tracked by Wall St. Rank held Repare Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.